Eye problems from cancer treatment registry
Part of Blood & lymphatic, Cancer clinical trials.
This study collects information and eye health data from people who have had cancer treatment, including stem cell transplants. It helps doctors understand how cancer therapies affect the eyes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had cancer treatment such as chemotherapy, immunotherapy, or a stem cell transplant.
- You do not have serious eye diseases (mild dry eye, cataracts, or glaucoma are okay).
- You are willing to sign a consent form and share your medical information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how an “ocular surface” condition can be identified using tests (biomarkers) and how a targeted treatment may help. You may qualify if you’re an adult receiving eye care at specific University of Maryland locations.
This trial is a general screening step for people who may have an eye (ocular) condition, or for family members of someone with an eye condition. The goal is to help match you to an eye research study by confirming your situation and whether you can safely participate.
This study observes patients who have had a stem cell transplant to understand and monitor chronic graft-versus-host disease affecting the eyes. It aims to learn more about this condition to improve future care.
This study looks at how common and how severe corneal nerve-related dryness is in people with chronic graft-vs-host disease (GVHD) after a stem cell transplant. It may help doctors understand which eye problems are most typical and how best to recognize them early.
This trial studies special stem cell lenses placed on the eye to treat chronic graft-versus-host disease (cGVHD) that causes dry, irritated eyes. It may help if standard eye treatments haven't worked well.
This study tests whether a new eye drop (rhPRG4) can safely reduce dry eye symptoms caused by graft-versus-host disease (GVHD). It compares the active drops to an inactive placebo to see if they provide better relief.
Hear when a new Graft Versus Host Disease in Eye trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.